References of "tchana-sato, Vincent"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailEffective arterial elastance as an index of pulmonary arterial load
Morimont, Philippe ULg; Lambermont, Bernard ULg; Ghuysen, Alexandre ULg et al

in European Journal of Heart Failure, Supplements (2007), 6

Detailed reference viewed: 13 (4 ULg)
Full Text
Peer Reviewed
See detailImage du mois. Rupture aortique intramediastinale massive
De Bast, Y.; TCHANA-SATO, Vincent; BRISBOIS, DENIS et al

in Revue Médicale de Liège (2005), 60(3), 135

Detailed reference viewed: 6 (0 ULg)
Full Text
Peer Reviewed
See detailPharmacological profile and therapeutic potential of BM-573, a combined thromboxane receptor antagonist and synthase inhibitor.
Ghuysen, Alexandre ULg; Dogné, Jean-Michel; Chiap, Patrice ULg et al

in Cardiovascular Drug Reviews (2005), 23(1), 1-14

BM-573 (N-terbutyl-N'-[2-(4'-methylphenylamino)-5-nitro-benzenesulfonyl]urea), a torsemide derivative, is a novel non-carboxylic dual TXA2 synthase inhibitor and receptor antagonist. The pharmacological ... [more ▼]

BM-573 (N-terbutyl-N'-[2-(4'-methylphenylamino)-5-nitro-benzenesulfonyl]urea), a torsemide derivative, is a novel non-carboxylic dual TXA2 synthase inhibitor and receptor antagonist. The pharmacological profile of the drug is characterized by a higher affinity for the thromboxane receptor than that of SQ-29548, one of the most powerful antagonists described to date, by a complete prevention of human platelet aggregation induced by arachidonic acid at a lower dose than either torsemide or sulotroban, and by a significantly prolonged closure time measured by the platelet function analyser (PFA-100). Moreover, at the concentrations of 1 and 10 microM, BM-573 completely prevented production of TXB2 by human platelets activated by 0.6 mM of arachidonic acid. BM-573 prevents rat fundus contraction induced by U-46619 but not by prostacyclin or other prostaglandins. Despite possessing a chemical structure very similar to that of a diuretic torsemide, BM-573 has no diuretic activity. BM-573 does not prolong bleeding time and, unlike some of the other sulfonylureas, has no effect on blood glucose levels. In vivo, BM-573 appears to have antiplatelet and antithrombotic activities since it reduced thrombus weight and prolonged the time to abdominal aorta occlusion induced by ferric chloride. BM-573 also relaxed rat aorta and guinea pig trachea precontracted with U-46619. In pigs, BM-573 completely antagonized pulmonary hypertensive effects of U-46619 and reduced the early phase of pulmonary hypertension in models of endotoxic shock and pulmonary embolism. Finally, BM-573 protected pigs from myocardial infarction induced by coronary thrombosis. These results suggest that BM-573 should be viewed as a promising therapeutic agent in the treatment of pulmonary hypertension and syndromes associated with platelet activation. [less ▲]

Detailed reference viewed: 11 (3 ULg)
Peer Reviewed
See detailRight ventricular diastolic function in acute pulmonary embolism
Morimont, Philippe ULg; segers, P.; Ghuysen, Alexandre ULg et al

Poster (2003)

Detailed reference viewed: 8 (6 ULg)